Xtx Topco LTD Exact Sciences Corp Transaction History

Xtx Topco LTD

$1.3 Billion
Q3 2024

A detailed history of Xtx Topco LTD transactions in Exact Sciences Corp stock. As of the latest transaction made, Xtx Topco LTD holds 27,372 shares of EXAS stock, worth $1.36 Million. This represents 0.14% of its overall portfolio holdings.

Number of Shares

27,372

Previous 26,109 4.84%

Holding current value

$1.36 Million

Previous $1.1 Million 68.9%

% of portfolio

0.14%

Previous 0.1%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$42.43 - $70.83 $53,589 - $89,458	1,263 Added 4.84%	27,372 $1.86 Million
Q2 2024 Aug 12, 2024	BUY	$41.33 - $74.26 $771,300 - $1.39 Million	18,662 Added 250.6%	26,109 $1.1 Million
Q1 2024 May 13, 2024	BUY	$56.27 - $73.77 $104,268 - $136,695	1,853 Added 33.12%	7,447 $514,000
Q4 2023 Feb 13, 2024	SELL	$59.06 - $75.72 $193,303 - $247,831	-3,273 Reduced 36.91%	5,594 $413,000
Q3 2023 Nov 13, 2023	SELL	$65.94 - $99.04 $134,517 - $202,041	-2,040 Reduced 18.7%	8,867 $604,000
Q2 2023 Aug 14, 2023	BUY	$62.68 - $95.05 $683,650 - $1.04 Million	10,907 New	10,907 $1.02 Million
Q3 2022 Nov 14, 2022	BUY	$31.97 - $49.37 $277,179 - $428,037	8,670 New	8,670 $282,000
Q1 2022 May 13, 2022	SELL	$57.56 - $82.54 $166,751 - $239,118	-2,897 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$72.5 - $100.68 $210,032 - $291,669	2,897 New	2,897 $225,000
Q2 2021 Aug 12, 2021	SELL	$93.66 - $139.27 $321,347 - $477,835	-3,431 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$116.57 - $155.01 $399,951 - $531,839	3,431 New	3,431 $452,000

Others Institutions Holding EXAS

# of Institutions

671

Shares Held

163M

Call Options Held

2.58M

Put Options Held

2.19M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $8.77B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

News

Stay updated on Xtx Topco LTD with notifications on news.

Account